As the activation of NF-κB is one of the reasons for the development of chemoresistance during cancer therapy, the inactivation of NF-κB by evodaimine may sensitize pancreatic cancer cells to anti-tumor therapies [148]. The gene discussed is NFKB1; the disease is cancer.